ArticleCancer gene therapy2020
Oncolytic activity of HF10 in head and neck squamous cell carcinomas.
Article in Cancer gene therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook.Vaccines · 2025Review
- Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.Oral oncology · 2024Review
- Review
- Microbiome and cancer: from mechanistic implications in disease progression and treatment to development of novel antitumoral strategies.Frontiers in immunology · 2024Review
- Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer.Cancers · 2023Review
- Adenovirus as a Vector and Oncolytic Virus.Current issues in molecular biology · 2023Review
- Evaluation of parameters for efficient purification and long-term storage of herpes simplex virus-based vectors.Molecular therapy. Methods & clinical development · 2022Article
- Oncolytic viruses in melanoma.Frontiers in bioscience (Landmark edition) · 2022Review
- The prognostic impact of the immune signature in head and neck squamous cell carcinoma.Frontiers in immunology · 2022Article
- The gamble between oncolytic virus therapy and IFN.Frontiers in immunology · 2022Review
- Review
- A review on the advances and challenges of immunotherapy for head and neck cancer.Cancer cell international · 2021Review
- The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.Viruses · 2021Review
- Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma.Molecular therapy oncolytics · 2021Article
- Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.International journal of molecular sciences · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent developments in therapeutic strategies have improved the prognosis of head and neck squamous cell carcinoma (HNSCC). Nevertheless, 5-year survival rate remains only 40%, necessitating new therapeutic agents. Oncolytic virotherapy entails use of replication-competent viruses to selectively kill cancer cells. We aimed to explore the potential of HF10 as an oncolytic virus against human or mouse HNSCC cell lines, and primary-cultured HNSCC cells. HF10 replicated well in all the HNSCC cells, in which it induced cytopathic effects and cell killing. Next, we investigated the oncolytic effects of HF10 in ear tumor models with human or mouse tumor cells. We detected HF10-infected cells within the ear tumors based on their expression of green fluorescent protein. HF10 injection suppressed ear tumor growth and prolonged overall survival. In the syngeneic model, HF10 infection induced tumor necrosis with infiltration of CD8-positive cells. Moreover, the splenocytes of HF10-treated mice released antitumor cytokines, IL-2, IL-12, IFN-alpha, IFN-beta, IFN-gamma, and TNF-alpha, after stimulation with tumor cells in vitro. The HF10-treated mice that survived their original tumor burdens rejected tumor cells upon re-challenge. These results suggested that HF10 killed HNSCC cells and induced antitumoral immunity, thereby establishing it as a promising agent for the treatment of HNSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.